Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.

Hironaga SatakeAkihito TsujiMasato NakamuraMasaaki OgawaTakeshi KotakeYukimasa HatachiHisateru YasuiAkinori TakaganeYoshihiro OkitaKumi NakamuraToshihide OnikuboMasahiro TakeuchiMasashi Fujii

Published in: International journal of clinical oncology (2018)

The FOLFOXIRI + panitumumab chemotherapy regimen was well tolerated by our patients with mCRC and showed promising anti-tumor activity. The recommended phase II dose was determined to be the same as the standard doses of this regimen used worldwide.

Keyphrases

wild type
phase ii
clinical trial
open label
squamous cell carcinoma
gene expression
randomized controlled trial
copy number
radiation therapy
genome wide
double blind